Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Applied DNA Sciences (NASDAQ: APDN) Begins Validation Testing of its Monkeypox Virus PCR Diagnostic Test

August 02, 2022 at 11:44 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Applied DNA Sciences, Inc. (NASDAQ: APDN) is a biotechnology company that is focused on producing and developing polymerase chain reaction (PCR)-based technologies for diagnostic testing. The company also develops nucleic acid-based therapies and DNA detection solutions for industrial supply chain security services.

Shares of the biotech company are skyrocketing 212% through early trading on Tuesday, August 2, 2022. Over the past three months, Applied DNA Sciences has seen average daily volume of 151,840 shares. However, volume of 43.1 million shares or dollar volume of around $97.41 million, has already exchanged hands through early trading.

The biotech company’s shares are soaring after the company announced it has launched analytical validation testing of its PCR-based diagnostic test for the monkeypox virus. The test will be developed as a type of New York State Department of Health (NYSDOH) Laboratory Developed Test (LDT). If validated, Applied DNA Sciences will submit its findings to the NYSDOH for approval and use in detecting monkeypox.

The company’s PCR test uses an A17L gene-target specific to the monkeypox virus, which is able to detect and differentiate the virus from other orthopoxviruses. After understanding the importance of PCR testing from the COVID pandemic, Applied DNA Sciences seeks to get a diagnostic solution available for market. This comes as the monkeypox virus only has continued its spread across the United States and world.

“Based on our experience with the COVID-19 pandemic, we are keenly aware of the crucial role PCR-based diagnostic tools can play in responding and helping to control public health outbreaks. With a proven workflow and testing services born of COVID-19, upon test approval, ADCL stands ready to apply its testing capacity in service of New Yorkers’ health,” stated Dr. James A. Hayward, president and CEO of Applied DNA Sciences.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Applied DNA Sciences (NASDAQ: APDN) Begins Validation Testing of its Monkeypox Virus PCR Diagnostic Test appeared first on Spotlight Growth.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article